BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia APRNewsWire • 06/24/22
BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not ClosedPRNewsWire • 06/21/22
BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in AtlantaPRNewsWire • 06/13/22
BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia APRNewsWire • 05/31/22
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 05/27/22
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth PlansPRNewsWire • 05/05/22
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform PresentationsPRNewsWire • 05/05/22
BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amETPRNewsWire • 05/04/22
BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/28/22
BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ETPRNewsWire • 04/13/22
5 Goldman Sachs Conviction List Stocks to Buy With 65% to 100% Upside Potential24/7 Wall Street • 03/28/22
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating BioMarin Pharmaceutical Inc.Newsfile Corp • 03/25/22
BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia APRNewsWire • 03/17/22